Based on the key indicators related to Virpax Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Virpax Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in January. At this time, Virpax Pharmaceuticals' Total Current Assets are fairly stable compared to the past year. Short Term Debt is likely to rise to about 846.5 K in 2024, whereas Short and Long Term Debt Total is likely to drop slightly above 1.2 M in 2024. Key indicators impacting Virpax Pharmaceuticals' financial strength include:
The essential information of the day-to-day investment outlook for Virpax Pharmaceuticals includes many different criteria found on its balance sheet. An individual investor should monitor Virpax Pharmaceuticals' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Virpax Pharmaceuticals.
Net Income
(15.95 Million)
Virpax
Select Account or Indicator
Market Cap
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Pb Ratio
Free Cash Flow Per Share
Roic
Net Income Per Share
Cash Per Share
Pocfratio
Interest Coverage
Pfcf Ratio
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Debt To Equity
Graham Net Net
Interest Debt Per Share
Debt To Assets
Short Term Coverage Ratios
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Quick Ratio
Net Income Per E B T
Cash Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Price Cash Flow Ratio
Debt Ratio
Cash Flow To Debt Ratio
Return On Assets
Price Fair Value
Return On Equity
Change In Cash
Net Borrowings
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Other Non Cash Items
Total Cash From Operating Activities
Change To Operating Activities
Issuance Of Capital Stock
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Netincome
Change To Liabilities
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Tangible Assets
Net Debt
Retained Earnings
Accounts Payable
Cash
Cash And Short Term Investments
Common Stock Total Equity
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Net Invested Capital
Short Long Term Debt
Total Current Assets
Capital Stock
Net Working Capital
Short Term Debt
Common Stock
Net Interest Income
Interest Expense
Selling General Administrative
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Depreciation And Amortization
Income Tax Expense
Probability Of Bankruptcy
Understanding current and past Virpax Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Virpax Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Virpax Pharmaceuticals' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Virpax Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Virpax Pharmaceuticals. Check Virpax Pharmaceuticals' Beneish M Score to see the likelihood of Virpax Pharmaceuticals' management manipulating its earnings.
Virpax Pharmaceuticals Stock Summary
Virpax Pharmaceuticals competes with Revelation Biosciences, Palisade Bio, Virax Biolabs, Quoin Pharmaceuticals, and RenovoRx. Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania. Virpax Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 7 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Virpax Pharmaceuticals Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
Cash flow analysis captures how much money flows into and out of Virpax Pharmaceuticals. It measures of how well Virpax is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Virpax Pharmaceuticals brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Virpax had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Virpax Pharmaceuticals has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
Comparative valuation techniques use various fundamental indicators to help in determining Virpax Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Virpax Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Virpax Pharmaceuticals competition to find correlations between indicators driving Virpax Pharmaceuticals's intrinsic value. More Info.
Virpax Pharmaceuticals is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, Virpax Pharmaceuticals' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Virpax Pharmaceuticals' earnings, one of the primary drivers of an investment's value.
Virpax Pharmaceuticals Systematic Risk
Virpax Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Virpax Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Virpax Pharmaceuticals correlated with the market. If Beta is less than 0 Virpax Pharmaceuticals generally moves in the opposite direction as compared to the market. If Virpax Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Virpax Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Virpax Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Virpax Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Virpax Pharmaceuticals Thematic Clasifications
Virpax Pharmaceuticals is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Today, most investors in Virpax Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Virpax Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Virpax Pharmaceuticals growth as a starting point in their analysis.
Virpax Pharmaceuticals December 1, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Virpax Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Virpax Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Virpax Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Virpax Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Virpax Pharmaceuticals's daily price indicators and compare them against related drivers.
When running Virpax Pharmaceuticals' price analysis, check to measure Virpax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virpax Pharmaceuticals is operating at the current time. Most of Virpax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Virpax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virpax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Virpax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.